Fritextsökning
Innehållstyper
-
Pharma Outsourcing igång på Stockholm Waterfront
-
Meeting with focus on South Korea and Japan’s life sciences
Large, complex and exciting – this is how Britta Stenson, Business Sweden, describes the life science markets of Japan and South Korea, which took centre stage ...
-
MSD discontinues two Keytruda trials
MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.
-
Joy at Egetis after positive CHMP opinion – ”The single most important milestone”
Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."
-
Lillys GLP-1-tablett nådde målen i typ 2-diabetesstudie
Läkemedelsbolaget Eli Lilly meddelar positiva resultat för GLP-1-tabletten orforglipron i två fas III-studier med typ 2-diabetespatienter.
-
Marie Gårdmark: “What to expect from Trump’s second term?”
One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...
-
Several departures at the top at Nykode
Members of both the management and the board are leaving the Norwegian biotech company Nykode.
-
SupraCube - In life Science
Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...
-
Kvinnohälsojätte sparkar vd:n efter misstänkt försäljningsfiffel
Amerikanska Organon skakas av en skandal, där vd:n fått gå efter misstankar om tvivelaktiga försäljningsmetoder.
-
Unmatched performance and flexibility in its class
The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.
-
New moves around Nykode's management – withdrawal of resignations
Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.
-
Optimize Your Visibility
ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.
-
How critical are the “Spermageddon” reports? – Researchers call for action
A much talked about meta-study indicates that sperm concentration in men’s seminal fluid has halved in 40 years. Experts in andrology that Life Science Sweden s...
-
Investigations against AstraZeneca: ”Chinese interests may be behind them”
Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...
-
TFS Trial Form Support AB
-
Drug development booms in Medicon Valley
When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...
-
From powder to implant
Quality assurance for additively manufactured implants.
-
Stockholm and Uppsala jointly form a life science cluster
Stockholm and Uppsala are strengthening cooperation in medical research and biotech.
-
Anna Törner: ”Mom, do you think you’ll ever get married again?”
”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence in...
-
Save the dates: ZEISS Quality Innovation Summit, October 22-24
Embark on a journey to the future of metrology.
-
Controlled Pneumatics: pushing the boundaries of pneumatics
Pressure, flow rate and movement can now be controlled very precisely, and with exactly the energy actually required. Controlled Pneumatics is the combination o...
-
Lundabolag ansöker om avnotering
Forskningsbolaget Abliva ansöker om avnotering av bolagets aktie från Nasdaq Stockholm.
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
Science Sweden has spoken to Swedish researchers in Alzheimer’s who voice cautious hope but also see further challenges.